BioCryst Swings to $1.12 EPS in Q4, Outpacing $0.07 Estimate and Prior Loss
BioCryst reported Q4 2025 EPS of $1.12, surpassing the consensus estimate of $0.07. The result marks a turnaround from a $0.13 per-share loss in the year-ago quarter.
1. Q4 2025 Earnings Beat Estimates
BioCryst reported Q4 2025 EPS of $1.12, surpassing the $0.07 consensus estimate and reversing a $0.13 per-share loss from Q4 2024. The swing into positive earnings highlights significantly improved financial performance and strengthened operational execution.
Related News
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
C
SpaceX Reveals $1.45B Bitcoin Stake Ahead of $1.75T IPO
C•
NEWP
Bolivia Overhauls Regulations as New Pacific Metals Poised for $700 Million Mining Boost
NEWP•
WPM
Wheaton Precious Metals Publishes Report Highlighting $9.4M Community Investment and MSCI AAA Rating
WPM•
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
Sources
FFSZ